Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03264157 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects
A Phase 2 study, sponsored by Bio Products Laboratory.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT03264157 is a Phase 2 study that has completed, run by Bio Products Laboratory. The registered enrollment target is 162 participants.
The verdict
NCT03264157, a Phase 2 study, has completed, sponsored by Bio Products Laboratory.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
A prospective, randomized, blinded, parallel-group, non-inferiority, phase II/III study of the safety and effectiveness of simulated post-exposure prophylaxis with BPL HRIG with co-administration of active rabies vaccine in healthy subjects.
Interventions
- DRUG HyperRAB
- DRUG HRIG
- BIOLOGICAL RabAvert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2017-12-08 |
| Est. Completion | 2018-07-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03264157
The ClinicalTrials.gov registry entry for NCT03264157 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bio Products Laboratory, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which HyperRAB is the first listed.
NCT03264157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03264157 about?
NCT03264157 is a clinical study titled "Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects". A prospective, randomized, blinded, parallel-group, non-inferiority, phase II/III study of the safety and effectiveness of simulated post-exposure prophylaxis with BPL HRIG with co-administration of active rabies vaccine in healthy subjects.
What is the current status of trial NCT03264157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2017-12-08. Estimated completion is 2018-07-13.
What interventions are being tested in trial NCT03264157?
The interventions under investigation include: HyperRAB (DRUG), HRIG (DRUG), RabAvert (BIOLOGICAL).
Who is sponsoring clinical trial NCT03264157?
This trial is sponsored by Bio Products Laboratory, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.